TORONTO, Ontario — The use of a topical ocular nonsteroidal anti-inflammatory drug (NSAID) before and after cataract surgery leads to meaningful reductions in postoperative macular edema in patients ...

Please provide your email address to receive an email when new articles are posted on . The decision is supported by positive visual acuity gains found in the phase 3 QUASAR trial. This is the fourth ...

In both studies, Vabysmo was found to be noninferior to aflibercept, with average vision gains being comparable between the treatment groups. The Food and Drug Administration (FDA) has approved ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved Vabysmo for the treatment of macular edema following retinal vein occlusion. This is the third ...

Repeat treatment with corticosteroid injections improved vision in people with persistent or recurrent uveitis-related macular edema better than two other therapies, according to results from a ...

This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. In 1999, I defined ...

Diabetic macular edema (DME) occurs when fluid accumulates in the retina due to high blood sugar damaging blood vessels. Research suggests the same vascular damage that causes DME also increases your ...

What Is Eylea HD, and Why Does It Matter? Eylea HD (aflibercept) is an injectable medicine used to treat certain eye conditions that can lead to vision loss. It works by blocking a protein called VEGF ...

Nicholas G. Anderson, MD, and Philip Niles, MD, MBA, provide an overview of diabetic macular edema (DME) and the impact of vision impairment on a patient’s quality of life. Jim Kenney, RPh, MBA: Dr.

Diabetic macular edema (DME) is a leading cause of vision loss in people with diabetes. It occurs when high blood sugar levels damage small blood vessels in the retina, the light-sensitive tissue at ...